Streetbeat News

INKT

MiNK Therapeutics, Inc.

Industry

Biotechnology

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Open

0.75

Mkt cap

30M

Volume

40K

High

0.77

P/E Ratio

-1.56

52-wk high

1.90

Low

0.74

Div yield

N/A

52-wk low

0.57

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares surged 11% after announcing a $5.8 million private placement financing to accelerate clinical trials of its leading therapy, MiNK-215. The company plans to sell 4.64 million shares at $1.25 each, a 25% premium to current prices, with the financing aimed at advancing MiNK-215's clinical trials targeting solid tumors. The PIPE deal is expected to close on May 14, 2024. Additionally, MiNK announced the appointment of Yekaterina Chudnovsky as Board Observer.

Portfolio Pulse from Dylan Berman

May 13, 2024 | 5:48 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings led the gainers with a 55.4% increase, while Applied DNA Sciences experienced the largest drop among the losers at 13.1%. Earnings reports were a common factor influencing stock movements, with companies like Dynatronics, Tarsus Pharmaceuticals, Fulcrum Therapeutics, and Fortrea Holdings recently releasing their financial results.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 12:06 pm

MiNK Therapeutics announced a private placement financing deal to raise $5.8 million, specifically aimed at accelerating the clinical trials of MiNK-215.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:31 am

In Monday's intraday session, several healthcare stocks experienced significant movements. Etao International Co led the gainers with a 96.6% increase, while Universe Pharmaceuticals topped the losers, declining by 18.2%. Other notable movers included Longeveron, Adlai Nortye, and Onconetix on the gainers' side, and Agenus, MiNK Therapeutics, and CNS Pharma among the losers.

Portfolio Pulse from Benzinga Insights

April 08, 2024 | 4:31 pm

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced promising preclinical data for MiNK-215, a novel CAR-iNKT cell therapy targeting colorectal cancer liver metastases, at the AACR Meeting. The therapy showed potent anti-tumor activity in human organoid models, including tumor stroma remodeling, immune activation, and enhanced tumor killing. The results suggest MiNK-215 could overcome limitations of current immunotherapies and work synergistically with other treatments like Agenus' botensilimab and balstilimab.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:02 pm

Byrna Technologies Inc. shares rose by 7.1% after reporting Q1 revenue that exceeded expectations and announcing a CFO transition. Other stocks also moved significantly in the mid-day session, with notable gainers including MediaCo Holding Inc., HUB Cyber Security Ltd., and GCT Semiconductor Holding, Inc., among others. Losers included Semantix, Inc., noco-noco Inc., and IM Cannabis Corp. Key reasons for movements include stake acquisitions, financing deals, MOUs, earnings reports, and analyst ratings.

Portfolio Pulse from Avi Kapoor

April 05, 2024 | 5:06 pm

In Friday's pre-market session, health care stocks showed significant movement. Protara Therapeutics led the gainers with a 40.3% increase, while Aesthetic Medical Intl experienced the largest drop among the losers, declining by 17.8%. Other notable movers include Candel Therapeutics and Etao International with substantial gains, and TC BioPharm and Imunon among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 12:09 pm

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on MiNK Therapeutics (NASDAQ:INKT) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 3:27 pm

MiNK Therapeutics (NASDAQ:INKT) reported a Q4 EPS loss of $(0.16), missing the consensus estimate of $(0.15) by 6.67%. However, this represents a 30.43% improvement over the $(0.23) per share loss from the same period last year.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 11:06 am

Numerous companies are scheduled to report their earnings on March 21, 2024, covering a wide range of industries from technology to healthcare. The reports include a mix of expected quarterly earnings and losses, with notable companies such as Welltower, Academy Sports, Exscientia, Direxion Daily CSI China Internet Index Bull 2X Shares, and Winnebago Industries among those reporting before the bell. After the bell, companies like Lululemon Athletica, Nike, FedEx, and Intellicheck will report, providing insights into their financial health and performance.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 10:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.